Status:
UNKNOWN
Evaluation of the Effect of tDCS on Cannabis Craving
Lead Sponsor:
Januel
Conditions:
Addiction to Cannabis
Eligibility:
All Genders
18-63 years
Phase:
NA
Brief Summary
Cannabis is the most frequently consumed drug in France and its use continues to increase. Over the 18-64 age group as a whole, experimentation with cannabis at least once in a lifetime increased from...
Eligibility Criteria
Inclusion
- Men or women between 18 and 65 years of age
- Right-Handers
- Diagnosis: Cannabis Use Disorder (according to DSM 5 criteria)
- Patient with no other drug or psychotherapeutic treatment for cannabis addiction ("naive" patients)
- Reported use of cannabis more than three times a week in the past three years
- Signing consent to participate in research
Exclusion
- Pregnancy or lack of effective contraception
- Patients with severe somatic disease
- Other addictions of "moderate" to "severe" intensity according to DSM 5 criteria (excluding tobacco and coffee)
- Patients undergoing antidepressant or neuroleptic or thyroid-regulating therapy.
- Contraindications to tDCS (presence of an intracranial metal body, intracranial hypertension)
- Topic that has already been stimulated by tDCS
- Patients under reinforced guardianship or curatorship
Key Trial Info
Start Date :
September 17 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 17 2021
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT04389528
Start Date
September 17 2018
End Date
December 17 2021
Last Update
May 15 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Youcef BENCHERIF
Maisons-Alfort, Île-de-France Region, France, 94700